

## “Fit for Filing” Speaker Bios

### **About Elizabeth Fox, MD**

Dr. Fox leads regulatory and clinical trial operations and clinical research prioritization and strategy at St Jude Children's Research Hospital. Nationally, she is the chair of the Developmental Therapeutics for the Children's Oncology Group and the UM1-funded Pediatric Early Phase Clinical Trials Network. Dr. Fox has expertise in quantitative clinical and pre-clinical pharmacology, pediatric clinical oncology, and clinical research trial design, including response and toxicity biomarker endpoint development. Dr Fox received her Medical Degree from Pennsylvania State University and her Masters of Clinical Research from Duke University. Her fellowship training and early career in pediatric oncology and drug development was at the Pediatric Branch of the Intramural Program of the NCI, Bethesda, MD. Before coming to St Jude in 2020, she was a Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania, Director of Developmental Therapeutics in Oncology at the Children's Hospital of Philadelphia, and PI of the Alex's Lemonade Stand Foundation Center of Excellence in Clinical Research and Pharmacology at the Children's Hospital of Philadelphia. Dr Fox has contributed to the FDA approval of 7 of the 50 oncology drugs currently approved for children with cancer. Her professional mission is to utilize clinical research to develop the most promising therapies for children and mentor clinician-scientists and a diverse clinical research workforce to foster innovation to improve the outcomes for children with catastrophic diseases.

### **About Elly Barry, MD, MMSc**

Dr. Barry is a board-certified pediatrician and pediatric hematologist/oncologist with over 15 years of experience in drug development. Before joining Day One Biopharmaceuticals in 2021, she was the Global Clinical Lead for Pediatric Oncology at Pfizer and Head of Pfizer's Pediatric Oncology Leadership Team, overseeing more than 10 pediatric oncology clinical programs. She has also held previous roles at Genzyme and Millenium/Takeda, which focused on developing oncology therapeutics in adults. Dr. Barry serves on the Industry Advisory Council for CureSearch and is an ACCELERATE Platform Steering Committee member. She is also a co-chair of the Children's Oncology Group Industry Relations Council. Dr. Barry is a graduate of the pediatric hematology/oncology fellowship program at the Dana Farber Cancer Institute and Children's Hospital Boston, and the pediatric residency program at Tufts. She received her M.D. at Yale University School of Medicine and a Masters in Medical Science degree from Harvard Medical School.

### **About Donna Ludwinski**

Donna Ludwinski's son Erik was diagnosed with high-risk neuroblastoma in 1991 at age 6. Despite his very poor prognosis, he recovered from the intensive therapy and was thriving but relapsed after 13 years. He died in 2010 after almost five years of treatment at age 24. Donna has been very involved in the patient/parent community for decades and is currently the Director of Research Advocacy at Solving Kids' Cancer in NY, and on the Family Support Team for SKC UK in London. A founding board member at CAC2, she serves on the Parent Advisory Council for New Approaches to Neuroblastoma Therapy (NANT) Consortium, FDA Patient Representative/Pediatric Oncologic Drug Advisory Committees (ODAC), NCI Central Review Board (CIRB) for COG trials, NCI Pediatric and Adolescent Solid Tumor Steering Committee PASTSC), DOD Rare Cancer Research Program Panel, and on the ACCELERATE Scientific Steering Committee. Donna has a BS in Chemical Engineering, raised four children, now lives in Virginia with her husband, and spends all her free time with her eight grandchildren.